Interaksi Ramipril dan Telmisartan

Ramipril dan Telmisartan: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Ramipril · berlaku sejak 2025-07-10

Mayor

Patients receiving the combination of telmisartan and ramipril did not obtain any benefit in the composite endpoint of cardiovascular death, MI, stroke and heart failure hospitalization compared to monotherapy, but experienced an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, or dialysis) compared with groups…

Peringatan dan perhatianmenyebut TelmisartanLihat label di DailyMed
Mayor

Concomitant use of telmisartan and ramipril is not recommended.

Peringatan dan perhatianmenyebut TelmisartanLihat label di DailyMed
Moderat

Dual Blockade of the Renin-Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Minor

Telmisartan The ONTARGET trial enrolled 25,620 patients >55 years old with atherosclerotic disease or diabetes with end-organ damage, randomized them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months.

Peringatan dan perhatianmenyebut TelmisartanLihat label di DailyMed

Dari label Telmisartan · berlaku sejak 2026-01-28

Mayor

Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker ( 5.6 )

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Patients receiving the combination of telmisartan tablets and ramipril did not obtain any additional benefit compared to monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with groups receiving telmisartan alone or ramipril alone.

Peringatan dan perhatianmenyebut RamiprilLihat label di DailyMed
Moderat

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen were observed.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAS) Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Minor

The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomizing them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months.

Peringatan dan perhatianmenyebut RamiprilLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.